Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 7 de 7
Obesity Facts ; 14(SUPPL 1):65, 2021.
Article in English | EMBASE | ID: covidwho-1255685


Introduction: Overweight and obesity are associated with a more severe COronaVirus Disease 19 (COVID-19). Adipose tissue related chronic inflammation could be a promoter for the occurrence of the cytokine storm that predicts aggravation of COVID-19. Primary aim was to investigate if this increased risk for more severe COVID-19 was associated with a higher inflammatory response. Methods: We enrolled patients <75 years old hospitalized in a medical COVID-19 ward with SARS-CoV-2 related pneumonia. Patients were classified according to Body Mass Index as normal weight, overweight and obesity. Laboratory parameters were measured at admission and every second day during the hospital stay. The time (in days) between the onset of COVID-19 symptoms and admission in the hospital and between the onset of COVID-19 symptoms and the day in which the maximal value was observed for each biochemical variable were also recorded. Results: 90 patients (64.4% males;median age 61 years) were enrolled. Invasive Mechanical Ventilation (IMV) was needed in 9% of the patients with a normal weight, in 32.4% of the patients with overweight and in 12.9% of the patients with obesity (p=0.045). Maximal C-Reactive Protein (CRP) level during hospital stay was 92 (48-122) mg/L in patients with a normal weight, 140 (82-265) mg/L in patients with overweight, and 117 (67-160) mg/L in patients with obesity (p=0.037). Conclusion: Patients with overweight had increased need in IMV than patients with obesity and normal weight;patients with overweight and obesity had higher peak of CRP than patients with normal weight during COVID-19.

Ann Oncol ; 32(7): 933-934, 2021 07.
Article in English | MEDLINE | ID: covidwho-1157115
Biochimica Clinica ; 44(SUPPL 2):S67, 2020.
Article in English | EMBASE | ID: covidwho-983996


Introduction. Saliva has been proposed as a valid alternative to naso-pharyngeal swabs for detecting viral SARS-CoV-2 RNA sequences. In addition salivary glands have been described as a potential SARSCoV-2 virus reservoir, thus supporting the search for antibodies in saliva. Furthermore, the non-invasive nature of saliva collection is conducive to self-collection, patients' compliance for repeated testing, and reduction of risk to operators, thus making saliva an eligible matrix in the SARS-CoV-2 diagnostic process. Aim. The aim of this study was to verify whether standardized and safe saliva collection is suitable for SARS-CoV-2 molecular detection and IgA class antibody measurement. Methods. A total of 49 COVID-19 patients hospitalized at the University-Hospital of Padova (Italy) and 326 subjects who underwent screening underwent naso-pharyngeal (NP) swab and saliva collection using Salivette®. Repeat blood collections were performed to evaluate hematological and coagulation parameters, biochemical markers of inflammation, and renal, liver, heart and pancreatic involvement in hospitalized patients. In all patients and subjects, saliva SARS-CoV-2 (gene E) rRT-PCR was undertaken in parallel with NP swabs. Salivary IgA and serum IgA, IgG, IgM were measured on samples from hospitalized patients. Results. NP swabs were SARSCoV-2 positive in 9/49 patients. The comparison with saliva testing was possible for 43/49 patients, 7 of whom shared positivity, and 35 negativity while in one, the saliva result, not NP-swab, was positive. Positive molecular testing results were significantly associated with disease duration (p=0.0049). All the 326 screened subjects were SARS-CoV-2 negative on both NP and saliva swabs. Among the 27 saliva samples tested for IgA, 18 were IgA positive. Salivary IgA positivity was significantly associated with pneumonia (p=0.002) and CRP values (p=0.0183), not with other clinical and molecular data, or with immunoglubulins in serum.Conclusions. The results reported in the present study demonstrate that a standardized and safe saliva collection method can be adopted to detect SARS-CoV-2 infection in alternative to NP-swabs. Preliminary data on salivary IgA also support the use of saliva in local adaptive immunity patient monitoring.

Ann Oncol ; 31(8): 1040-1045, 2020 08.
Article in English | MEDLINE | ID: covidwho-186722


BACKGROUND: Cell entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) depends on binding of the viral spike (S) proteins to angiotensin-converting enzyme 2 and on S protein priming by TMPRSS2. Inhibition of TMPRSS2 may work to block or decrease the severity of SARS-CoV-2 infections. Intriguingly, TMPRSS2 is an androgen-regulated gene that is up-regulated in prostate cancer where it supports tumor progression and is involved in a frequent genetic translocation with the ERG gene. First- or second-generation androgen-deprivation therapies (ADTs) decrease the levels of TMPRSS2. Here we put forward the hypothesis that ADTs may protect patients affected by prostate cancer from SARS-CoV-2 infections. MATERIALS AND METHODS: We extracted data regarding 9280 patients (4532 males) with laboratory-confirmed SARS-CoV-2 infection from 68 hospitals in Veneto, one of the Italian regions that was most affected by the coronavirus disease 2019 (COVID-19) pandemic. The parameters used for each COVID-19-positive patient were sex, hospitalization, admission to intensive care unit, death, tumor diagnosis, prostate cancer diagnosis, and ADT. RESULTS: There were evaluable 9280 SARS-CoV-2-positive patients in Veneto on 1 April 2020. Overall, males developed more severe complications, were more frequently hospitalized, and had a worse clinical outcome than females. Considering only the Veneto male population (2.4 million men), 0.2% and 0.3% of non-cancer and cancer patients, respectively, tested positive for SARS-CoV-2. Comparing the total number of SARS-CoV-2-positive cases, prostate cancer patients receiving ADT had a significantly lower risk of SARS-CoV-2 infection compared with patients who did not receive ADT (OR 4.05; 95% CI 1.55-10.59). A greater difference was found comparing prostate cancer patients receiving ADT with patients with any other type of cancer (OR 4.86; 95% CI 1.88-12.56). CONCLUSION: Our data suggest that cancer patients have an increased risk of SARS-CoV-2 infections compared with non-cancer patients. However, prostate cancer patients receiving ADT appear to be partially protected from SARS-CoV-2 infections.

Androgen Antagonists/therapeutic use , Betacoronavirus , Coronavirus Infections/prevention & control , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Population Surveillance , Prostatic Neoplasms/drug therapy , Aged , Aged, 80 and over , COVID-19 , Coronavirus Infections/diagnosis , Coronavirus Infections/epidemiology , Humans , Italy/epidemiology , Male , Middle Aged , Pneumonia, Viral/diagnosis , Pneumonia, Viral/epidemiology , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/epidemiology , Risk Factors , SARS-CoV-2